mauric
ralph
hilleman
one
greatest
microbiologistsvaccinologist
time
play
key
role
develop
vaccin
asian
flu
hong
kong
flu
six
decad
spent
merck
compani
leadership
innov
blaze
new
trail
virolog
epidemiolog
immunolog
cancer
research
vaccin
develop
unmatch
work
result
current
vaccin
use
prevent
measl
mump
hepat
b
chickenpox
mening
pneumonia
save
million
live
across
globe
need
close
cooper
public
privat
agenc
includ
donor
promot
research
vaccinolog
reemphas
recent
global
health
crise
ebola
zika
virus
well
annual
influenza
viru
threat
erad
mani
diseas
feasibl
requir
polit
support
resourc
vaccin
develop
harmon
vaccin
polici
achiev
hilleman
work
mani
collabor
academ
center
industri
manag
led
research
develop
team
produc
worldchang
achiev
mauric
ralph
hilleman
creator
merck
compani
vaccin
use
routin
child
care
courtesi
mr
lorrain
hilleman
hilleman
join
walter
reed
armi
medic
center
chief
depart
respiratori
diseas
assign
studi
respiratori
ill
militari
signific
devis
scienc
strategi
deal
influenza
demonstr
influenza
virus
underw
gradual
progress
minor
antigen
characterist
call
drift
shift
basi
modern
influenza
vaccin
strategi
olanski
lancet
age
hilleman
recruit
pharmaceut
compani
merck
compani
west
point
pennsylvania
lead
viru
vaccin
research
program
next
year
continu
direct
merck
institut
vaccinolog
anoth
yearsaft
compulsori
retir
merck
research
lab
age
death
age
hilleman
team
creat
experiment
licens
human
anim
vaccin
includ
use
current
offer
protect
measl
mump
chickenpox
rubella
hepat
hepat
b
pneumococc
pneumonia
mening
pandem
influenza
chlamydia
hilleman
led
develop
asian
flu
vaccin
import
allevi
worldwid
pandem
influenza
remain
yearli
occurr
horrend
swine
flu
pandem
kill
ten
million
peopl
primarili
young
men
new
virul
influenza
type
emerg
earli
februari
lifethreaten
wave
flu
spread
across
china
report
case
hong
kong
still
microbiologist
walter
reed
armi
medic
center
hilleman
suspect
could
becom
pandem
threat
coin
term
asian
flu
obtain
sampl
viru
ill
us
serviceman
determin
peopl
lack
antibodi
protect
new
influenza
viru
initi
vaccin
product
send
viru
sampl
manufactur
urg
develop
vaccin
within
four
month
produc
million
dose
vaccin
reduc
us
epidem
caus
estim
death
unit
state
worldwid
two
million
peopl
die
asian
flu
subsequ
new
influenza
strain
continu
emerg
asia
hilleman
activ
develop
vaccin
hong
kong
influenza
pandem
continu
threat
annual
flu
epidem
world
health
organ
develop
new
pandem
guidelin
upgrad
pandemicprepared
plan
cooper
vaccin
manufactur
nation
public
health
agenc
especi
address
need
quicker
develop
distribut
influenza
vaccin
colleg
physician
philadelphia
work
academ
scientist
also
respons
field
work
collect
sampl
vaccin
develop
well
administr
scientif
leadership
result
field
test
product
mani
newor
improvedvaccin
character
isol
antigen
perform
basicand
process
research
well
clinic
studi
way
manufactur
process
result
fundament
breakthrough
vaccin
develop
tabl
show
timelin
vaccin
licens
unit
state
leonard
hayflick
born
philadelphia
pennsylvania
graduat
bachelor
degre
microbiolog
univers
pennsylvania
gi
us
veteran
bill
complet
armi
servic
continu
studi
receiv
master
degre
award
full
scholarship
toward
phd
medic
microbiolog
chemistri
work
univers
texa
galveston
hayflick
learn
techniqu
cell
cultur
produc
larg
number
select
cell
long
term
surviv
replic
live
control
condit
fetal
cell
consid
safer
cell
line
latter
could
genet
abnorm
contain
undetect
virus
anim
origin
carri
cancer
gene
famou
hela
cell
line
oldest
commonli
use
human
cell
line
deriv
cervic
cancer
cell
henrietta
lack
patient
die
cancer
cell
line
extrem
readili
grown
surviv
use
extens
scientif
research
includ
product
inactiv
salk
vaccin
consider
controversi
surround
even
today
sampl
taken
without
patient
permiss
possibl
carri
cancer
genet
materi
lung
cell
human
fetal
specimen
develop
hayflick
legal
abort
stockholm
consid
promis
controversi
due
ethic
question
disput
sourc
ownership
distribut
right
hayflick
strain
develop
wistar
institut
philadelphia
call
wide
accept
altern
primari
monkey
kidney
hela
cell
provid
cell
line
normal
human
embryon
tissu
normal
chromosom
constitut
transfer
tumor
anim
model
cell
strain
accept
europ
hayflick
cell
line
approv
use
vaccin
sinc
becam
wide
use
highli
character
normal
human
cell
popul
world
provid
hayflick
stanley
plotkin
use
develop
new
rubella
viru
growth
result
vaccin
licens
also
use
product
first
oral
polio
vaccin
made
continu
propag
cell
strain
hayflick
renown
professor
gerontolog
studi
univers
california
san
francisco
landmark
studi
character
hayflick
limit
cellular
age
basic
longev
studi
contribut
vaccinolog
cell
line
along
chick
embryo
cell
use
manufactur
human
viru
vaccin
worldwid
vaccin
use
cell
immun
mani
hundr
million
peopl
includ
oral
poliomyel
sabin
measl
rubella
varicella
mump
rabi
adenovirus
hepat
vaccin
hilleman
team
use
cell
develop
major
vaccin
current
recommend
childhood
routin
immun
led
develop
vaccin
hilleman
produc
attenu
measl
vaccin
deriv
viru
isol
john
ender
still
use
today
hillman
rubella
vaccin
also
attenu
ie
less
like
caus
diseas
still
induc
antibodi
vaccin
person
vaccin
remain
use
today
hilleman
isol
mump
viru
throat
swab
fiveyear
old
daughter
develop
new
vaccin
licens
offici
name
jeryl
lynn
hilleman
icon
measl
mump
rubella
mmr
combin
vaccin
licens
fda
use
worldwid
hilleman
also
produc
hong
kong
pandem
influenza
vaccin
meningococc
polysaccharid
vaccin
licens
mani
decad
search
pneumococc
pneumonia
vaccin
merck
licens
polysaccharid
vaccin
ie
long
chain
sugar
molecul
make
cell
wall
bacteria
offer
protect
type
pneumococc
bacteria
vaccin
extend
includ
type
pneumococc
bacteria
base
work
select
robert
austrianunivers
pennsylvania
school
medicinewho
isol
cell
line
type
pneumococc
bacteria
type
appropri
vaccin
austrian
provid
inform
hilleman
associ
merck
develop
vaccin
polysaccharid
outer
coat
bacteria
colleg
physician
philadelphia
vaccin
timelin
hilleman
work
base
cooper
lead
scientist
translat
scientif
studi
safe
effect
vaccin
suitabl
mass
product
measl
vaccin
went
long
process
develop
mani
key
player
includ
john
ender
samuel
l
katz
isol
measl
viru
blood
sampl
david
edmonston
subsequ
call
edmonston
strain
work
scientist
ender
katz
turn
strain
vaccin
licens
unit
state
attenu
ie
use
live
weaken
measl
strain
would
caus
diseas
rather
act
vaccin
promot
product
suffici
antibodi
protect
subsequ
exposur
natur
measl
viru
hilleman
colleagu
develop
improv
edmonstonend
strain
remain
primari
measl
vaccin
use
unit
state
hilleman
develop
first
viral
subunit
vaccin
base
work
baruch
blumberg
wolf
szmuness
australian
antigen
cell
membran
surfac
protein
hepat
b
viru
rather
entir
viru
produc
vaccin
licens
hepat
b
recombin
vaccin
inexpens
produc
use
worldwid
newborn
prevent
later
develop
chronic
liver
diseas
cirrhosi
liver
cancer
recombin
hepat
b
vaccin
base
hepat
b
surfac
antigen
hbsag
gene
insert
yeast
cell
free
concern
associ
human
blood
product
breakthrough
vaccinolog
recombin
vector
vaccin
method
promis
improv
vaccin
research
product
lower
cost
temperatur
stabil
eas
administr
also
provid
hope
faster
vaccin
respons
emerg
infecti
agent
hilleman
produc
first
us
fda
licens
congug
vaccin
base
fat
bacteri
cell
wall
attach
protein
produc
hemophilu
influenza
type
b
hib
vaccin
vaccin
protect
seriou
respiratori
infect
babi
age
month
dramat
reduct
case
death
within
year
hilleman
also
develop
varicella
chicken
pox
hepat
vaccinesboth
licens
import
public
health
benefit
hilleman
travel
world
advisor
world
health
organ
mani
public
health
infecti
diseas
group
outstand
scientif
endeavor
led
vaccin
save
million
live
extend
human
life
expect
improv
economi
numer
countri
receiv
mani
profession
award
lifetim
achiev
never
receiv
muchdeserv
nobel
prize
level
public
profession
recognit
given
great
scientist
immunolog
pasteur
anthrax
rabi
vaccin
salk
sabin
poliomyel
vaccin
hilleman
death
report
mani
scientif
journal
major
news
media
laudatori
obituari
hilleman
innov
advanc
file
vaccinolog
provid
base
progress
vaccin
develop
address
mani
old
devast
diseas
includ
malaria
tuberculosi
dengu
well
meet
challeng
rel
new
diseas
transmit
wider
habitat
becom
endem
includ
spread
diseas
west
nile
viru
wnv
lassa
fever
rift
valley
fever
rvf
middl
east
respiratori
syndrom
coronaviru
merscov
chikungunya
longknown
diseas
dengu
yellow
fever
spread
via
travel
vector
bring
older
diseas
new
habitat
recent
alarm
epidem
ebola
viru
west
africa
kill
peopl
zika
viru
known
sinc
burst
epidem
brazil
spread
wide
south
american
caribbean
southern
us
state
ebola
zika
vaccin
declar
global
public
health
emerg
emerg
viral
diseas
societi
return
era
infecti
diseas
control
depend
popul
support
educ
hygien
vector
control
relentless
wellfund
search
safe
effect
vaccin
develop
nation
academi
press
new
scientif
breakthrough
may
also
lead
improv
current
vaccin
lower
cost
eas
administr
increas
global
coverag
rate
enhanc
effect
safeti
valu
benefit
vaccin
diseas
control
includ
prevent
infect
clinic
subclin
poliomyel
hepat
b
cancer
eg
cancer
liver
cervix
prevent
mitig
diseas
sever
pneumococc
pneumonia
influenza
proven
capac
elimin
even
erad
diseas
caus
agent
natur
smallpox
poliomyel
measl
vaccin
reduc
mortal
morbid
complic
protect
individu
also
commun
reduc
spread
diseas
vaccin
protect
immun
individu
suffici
percentag
popul
vaccin
provid
herd
immun
critic
portion
communityov
percenti
immun
result
protect
vulner
individu
may
immun
due
neglect
refus
age
group
underimmun
childhoodeg
receiv
one
dose
measl
vaccin
underag
immunizationeg
earli
infancyor
autoimmun
diseaseeg
rheumatoid
arthriti
system
lupu
erythematosu
crohn
diseasewith
weaken
immun
systemeg
hiv
positiveor
medic
immunosuppress
eg
cancer
treatment
organ
transplant
immun
individu
herd
immun
vital
factor
public
health
level
immun
coverag
requir
herd
immun
vari
differ
diseas
organ
case
measl
requir
percent
immun
coverag
long
period
time
adequ
twodos
polici
monitor
fund
qualiti
assur
immun
program
adequaci
mean
coverag
popul
risk
diseas
group
inadequ
vaccin
becom
unexpectedli
vulner
exampl
recent
import
spread
measl
mump
america
diseas
previous
consid
elimin
new
challeng
emerg
requir
increas
vaccin
coverag
includ
tetanu
diphtheria
pertussi
influenza
pregnant
women
famili
member
care
giver
protect
newborn
vulner
immun
complet
herd
immun
ie
immun
vaccin
among
high
percentag
popul
suffici
reduc
risk
transmiss
isol
case
vari
differ
diseas
must
achiev
maintain
reduc
potenti
transmiss
diseas
vulner
peopl
peopl
immun
defici
due
infect
hiv
cancer
chemotherapi
immunodefici
diseas
case
give
rubella
vaccin
boy
well
girl
reduc
elimin
circul
viru
prevent
infect
pregnanc
lead
congenit
rubella
syndrom
infant
diseas
result
lifelong
disabl
see
chapter
vaccin
program
reach
higher
percentag
vulner
popul
elimin
diseas
local
achiev
without
global
erad
caus
microorgan
global
erad
infecti
diseas
seem
imposs
dream
achiev
smallpox
demonstr
human
diseas
anim
hostsuch
smallpox
poliomyel
measl
mump
rubellacould
also
erad
effort
erad
poliomyel
come
close
success
erad
measl
rubella
target
achiev
vaccin
prevent
cancer
import
advanc
public
health
success
hepat
b
immun
see
figur
prevent
mani
case
liver
cirrhosi
liver
cancer
global
impact
recent
slowli
increas
use
human
papilloma
viru
hpv
vaccin
prevent
cervic
cancer
reduc
pap
smear
screen
ultim
hpv
vaccin
domin
factor
control
hpv
infect
caus
cancer
cervix
addit
boy
also
immun
reduc
spread
viru
heterosexu
intercours
well
reduc
increas
rate
oral
anal
cancer
homosexu
relat
search
vaccin
cancer
benefit
signific
progress
recent
decad
genet
microbiolog
comput
molecular
scienc
scientif
manufactur
advanc
led
hilleman
produc
vaccin
econom
health
sector
benefit
mani
nation
increas
use
prevent
pneumococc
pneumonia
mening
measl
reduc
depend
antibiot
complic
diseas
factor
reduc
antibiot
usag
thu
slow
develop
antibiot
resist
vaccin
protect
peopl
chronic
medic
condit
chronic
lung
heartor
kidney
diseas
success
pneumococc
pneumonia
influenza
vaccin
reduc
seriou
complic
hospit
avoid
death
see
figur
global
estim
million
episod
seriou
pneumococc
diseas
occur
annual
includ
pneumonia
mening
sepsi
mainli
children
age
five
year
result
death
mostli
lowand
middleincom
countri
pneumococc
conjug
vaccin
pcv
first
licens
provid
protect
seven
common
pneumococc
serotyp
recommend
vaccin
includ
routin
immun
program
particularli
high
incid
countri
new
pcv
formul
protect
serotyp
becam
avail
provid
better
coverag
serotyp
common
lowand
middleincom
countri
pneumococc
polysaccharid
vaccin
serotyp
pneumococc
bacteria
use
recommend
adult
year
older
children
high
risk
increasingli
older
adult
vaccin
recommend
children
adult
includ
pregnant
women
hilleman
demonstr
valu
combin
vaccin
enorm
success
measl
mump
rubella
vaccin
mmr
later
ad
inactiv
poliomyel
vaccin
ipv
varicella
chickenpox
vaccin
standard
vaccin
combin
expand
addit
polio
ipv
along
hemophilu
influenza
hib
combin
diphtheria
pertussi
tetanu
dpt
pentaval
vaccin
given
infant
simultan
rotaviru
mening
b
pneumococc
pneumonia
vaccin
without
loss
effect
benefit
includ
better
complianc
improv
coverag
inject
safeti
less
cost
fewer
visit
medic
servic
vaccin
also
provid
protect
safeti
potenti
biolog
form
bioterror
smallpox
anthrax
potenti
respiratori
infecti
agent
largescal
epidem
measl
spread
across
europ
travel
spread
measl
north
south
america
measl
case
regist
european
countri
austria
belgium
bulgaria
czech
republ
hungari
franc
germani
iceland
itali
portug
romania
spain
switzerland
sweden
estim
total
case
measl
romania
affect
countri
measl
patient
report
januari
april
accord
european
center
diseas
prevent
control
ecdc
total
death
europ
occur
romania
portug
switzerland
bulgaria
also
measl
fatal
ecdc
explor
nation
immun
inform
system
improv
monitor
immun
coverag
local
geograph
level
link
individu
immun
histori
health
outcom
data
vaccin
safeti
effect
well
failur
educ
materi
vaccin
research
produc
provid
recipi
import
secondari
measl
case
appear
california
state
allow
person
belief
exempt
easili
overrid
law
requir
full
immun
two
dose
mmr
vaccin
children
young
adult
attend
school
led
extrem
low
mmr
vaccin
rate
school
particularli
privat
school
even
zero
coverag
kindergarten
outbreak
led
chang
californian
law
requir
parent
consult
local
public
health
offic
requir
medic
certif
state
medic
reason
exempt
process
make
difficult
parent
deni
immun
children
put
unimmun
children
risk
due
highli
infecti
natur
measl
new
immun
requir
california
result
increas
coverag
mmr
vaccin
percent
scienc
behind
vaccin
develop
increas
capac
markedli
recent
year
genet
immunolog
enter
new
sphere
research
vaccin
combat
cancer
genet
diseas
expect
play
major
role
clinic
medicin
public
health
come
decad
case
measl
hepat
b
prime
exampl
vaccin
develop
partnership
mani
contribut
laboratori
manufactur
public
health
leader
share
inform
scientif
advanc
lead
reduc
global
mortal
rate
scientist
manufactur
work
togeth
creat
hbv
vaccin
produc
use
one
element
cellular
wall
viru
instead
whole
viru
increas
safeti
vaccin
hilleman
later
develop
first
immun
recombin
vaccin
contribut
applic
advanc
genet
scienc
vaccinolog
futur
provid
lowcost
wide
effect
new
approach
vaccin
public
trust
vaccin
becom
import
global
health
issu
neg
attitud
due
fear
fals
highli
public
sideeffect
hesit
among
doctor
itali
germani
make
vaccin
mandatori
health
offici
warn
falloff
vaccin
rate
trigger
measl
epidem
european
countri
case
measl
doubl
number
first
two
month
compar
report
ecdc
case
almost
ten
time
number
notwithstand
astonish
success
vaccin
save
million
live
promot
civil
societi
vaccin
develop
product
implement
mani
ethic
issu
controversi
rang
ideolog
antivaccinaton
profession
jealousi
controversi
along
econom
legal
disput
cell
line
vaccin
product
alleg
vaccin
caus
diseas
children
slow
adopt
lifesav
vaccin
inadequ
resourc
alloc
develop
countri
lack
harmon
vaccin
polici
other
antivaccination
around
sinc
day
jenner
discoveri
vaccin
prevent
smallpox
th
centuri
continu
present
time
see
chapter
recent
rate
parent
refus
vaccin
increas
due
part
increas
public
skeptic
public
health
profession
policymak
pharmaceut
industri
reduc
public
health
awar
also
due
success
control
nearelimin
mani
dread
infecti
diseas
smallpox
poliomyel
today
parent
health
care
staff
doctor
never
seen
diseas
prevent
vaccin
understand
graviti
public
anxieti
surround
vaccin
rose
unit
kingdom
respons
concern
safeti
pertussi
vaccin
result
declin
immun
coverag
return
well
control
diseas
mid
uk
uptak
mmr
vaccin
fell
peak
percent
age
two
percent
uptak
fall
percent
part
london
seriou
implic
mutual
protect
popul
ie
herd
immun
us
elsewher
recent
outbreak
pertussi
diphtheria
spread
import
measl
decad
control
rais
need
ensur
immun
pregnant
women
close
famili
member
protect
fetu
newborn
seriou
prevent
infect
infant
immun
protect
take
hold
harm
creat
public
fraudul
uneth
research
activ
advers
impact
profession
public
percept
matter
vaccin
articl
publish
lancet
andrew
wakefield
purport
show
mmr
vaccin
caus
autism
creat
storm
public
concern
parent
refus
mmr
vaccin
media
investig
profession
studi
prove
studi
fabric
mani
reliabl
studi
sinc
disprov
claim
follow
ethic
investig
uk
gener
medic
council
wakefield
medic
licens
revok
articl
partial
retract
lancet
fulli
withdrawn
journal
howev
despit
media
coverag
retract
articl
credibl
vaccinationsspecif
mmr
vaccinein
eye
public
damag
substanti
alleg
although
proven
fabric
continu
wide
believ
spread
via
internet
social
media
popular
resist
vaccin
legal
ethic
question
reflect
current
controversi
unit
state
opt
mandatori
vaccin
contribut
measl
outbreak
diseas
consid
erad
mani
year
ago
compulsori
immun
current
polit
accept
due
concern
parent
right
refus
activ
lobbi
internet
public
media
govern
medicin
state
mandat
requir
certif
complet
immun
well
establish
unit
state
us
state
legisl
requir
specifi
vaccin
student
howev
exempt
allow
medic
reason
reason
religi
belief
state
allow
philosoph
exempt
object
immun
person
moral
belief
nation
confer
state
legislatur
pediatrician
unit
state
report
increas
refus
parent
immun
children
prompt
american
academi
pediatr
aap
american
medic
associ
ama
american
colleg
physician
recommend
elimin
nonmed
exempt
state
immun
law
call
state
legisl
increas
limit
exempt
claus
philosoph
reason
refus
vaccin
seen
pose
threat
children
well
form
child
neglect
child
car
without
appropri
child
car
seat
part
action
stimul
concern
increas
resist
parent
vaccin
along
return
previous
control
diseas
failur
vaccin
form
child
neglect
public
privat
sector
includ
pharmaceut
industri
contribut
greatli
increas
vaccin
coverag
rate
partnership
remain
vital
vaccinolog
senior
staff
member
merck
respons
vaccin
develop
major
pharmaceut
compani
hilleman
conduct
industryfund
research
contribut
led
directli
manufactur
major
vaccin
creat
latter
half
th
centuri
remain
vital
public
health
us
global
role
privat
pharmaceut
industri
need
recogn
crucial
advanc
field
equal
depend
scientist
univers
public
research
institut
contribut
knowledg
base
enabl
breakthrough
vaccin
product
distribut
period
larg
epidem
two
deadli
new
virus
ebola
zika
design
global
health
crise
justifi
concern
could
spread
rapidli
mani
part
world
zika
viru
transmit
pregnant
woman
anophel
mosquito
sexual
relat
zika
infect
partner
may
produc
mild
ill
tragic
effect
fetus
result
seriou
birth
defect
includ
small
head
size
ie
microcephali
brain
damag
race
develop
effect
vaccin
must
involv
cooper
achiev
work
vaccin
within
sever
year
media
concern
remind
skeptic
essenti
role
vaccin
research
cooper
govern
donor
academ
industri
scientist
promot
mauric
hilleman
life
work
long
time
gap
avail
proof
vaccin
success
adopt
global
ethic
issu
reduc
global
health
inequ
well
question
prioriti
resourc
alloc
public
health
adopt
implement
vaccin
slow
respond
import
advanc
especi
lowincom
countri
policymak
tradit
given
health
low
prioriti
government
financ
delay
vaccin
adopt
lead
prevent
infect
high
rate
ill
death
human
miseri
slow
econom
progress
lack
harmon
vaccin
polici
major
profession
public
polici
ethic
issu
limit
factor
achiev
full
potenti
proven
success
safe
vaccin
europ
european
union
still
common
harmon
immun
program
case
even
countri
contribut
massiv
measl
epidem
sinc
benefit
societi
vaccin
enorm
save
live
reduc
morbid
also
reduc
health
care
cost
vaccin
lifesav
costeffect
support
nation
govern
intern
donor
program
alongsid
buildup
public
health
educ
infrastructur
develop
within
recipi
countri
vaccin
crucial
reduc
child
ill
birth
defect
eg
congenit
rubella
syndrom
vaccin
help
men
women
especi
children
healthi
live
without
morbid
mani
previous
common
childhood
diseas
eg
poliomyel
also
lessen
infect
among
peopl
chronic
medic
disabl
condit
pneumococc
pneumonia
influenza
vaccin
reduc
diseas
high
mortal
rate
promot
econom
growth
support
world
bank
econom
analys
success
vaccin
also
increas
equiti
societi
reduc
diseas
often
common
among
poorer
popul
expans
vaccin
coverag
decad
vaccin
fund
bill
melinda
gate
foundat
world
poorest
countri
estim
save
us
billion
acut
care
cost
increas
product
valu
least
us
billion
stack
et
al
cdc
estim
save
avert
direct
health
care
cost
us
billion
usd
one
trillion
dollar
societ
cost
cohort
children
born
unit
state
whitney
et
al
sinc
world
bank
econom
analyst
accept
econom
benefit
lowand
mediumincom
countri
lmic
reduc
child
mortalitymostli
result
reduc
morbid
mortal
infecti
diseasesi
vital
econom
social
advanc
nearli
univers
use
hepat
b
vaccin
newborn
help
prevent
mothertochild
transmiss
subsequ
prevent
liver
cirrhosi
liver
cancer
enorm
econom
valu
health
system
vaccin
prevent
spread
hepat
avail
use
mani
countri
vaccin
seriou
diseas
hepat
c
regrett
yet
develop
although
effect
lifesav
treatment
avail
costli
effect
vaccin
would
bring
greater
benefit
advanc
vaccin
coverag
lowand
middleincom
countri
lmic
brazil
russian
feder
india
china
south
africa
bric
vari
wide
review
cost
effect
econom
benefit
studi
vaccin
lmic
conclud
vaccin
bring
import
econom
benefit
recommend
policymak
consid
vaccin
effici
invest
exampl
health
econom
social
benefit
vaccin
hemophilu
influenza
b
hib
pneumococc
pneumonia
rotaviru
vaccin
coverag
bric
countri
estim
us
billion
annual
see
tabl
immun
avert
estim
two
three
million
death
everi
year
diphtheria
tetanu
pertussi
whoop
cough
measl
howev
addit
million
death
could
prevent
global
vaccin
coverag
improv
percent
percent
gavi
global
vaccin
allianc
major
entiti
work
increas
coverag
lowincom
countri
gavi
global
allianc
vaccin
implement
support
unicef
world
bank
gate
foundat
pharmaceut
compani
other
sinc
found
gavi
help
financ
adopt
vaccin
lowincom
countri
depend
extern
support
financ
vaccin
percentag
lowincom
countri
financ
vaccin
nation
budget
rose
percent
percent
modest
increas
nation
govern
share
routin
immun
rise
percent
percent
studi
review
public
countri
introduc
rotaviru
vaccin
nation
routin
immun
program
sinc
substanti
reduct
found
rotaviru
allcaus
acut
gastroenter
age
hospit
age
mortal
among
children
age
one
age
five
year
measl
highli
contagi
potenti
fatal
diseas
lead
caus
death
among
young
children
see
box
effort
control
elimin
ultim
erad
measl
part
intern
organ
strategi
econom
analysi
levin
et
al
indic
measl
erad
costeffect
scenario
six
countri
studi
global
global
measl
rubella
strateg
plan
consid
econom
benefit
promot
public
health
econom
growth
power
justif
target
measl
rubella
erad
high
prioriti
lmic
recent
year
mani
costeffect
studi
vaccin
hepat
b
rotaviru
human
papilloma
viru
influenza
shown
vaccin
effect
econom
tool
signific
health
benefit
global
target
rubella
erad
along
measl
achiev
requir
new
tactic
europ
harmon
immun
program
across
region
certainli
european
union
free
border
cross
member
state
largescal
refuge
entri
without
evid
past
immun
tool
exist
outstand
vaccin
combin
especi
mmr
vaccin
creat
hilleman
measl
rubella
controland
ultim
eradicationar
within
capac
welll
public
health
polici
resourc
see
box
scienc
vaccinolog
depend
academ
research
privat
sector
limit
number
vaccin
produc
world
drumbeat
public
health
emerg
centuri
sar
influenza
ebola
zika
viru
epidem
indic
problem
long
known
diseas
malaria
hiv
tb
dengu
west
nile
fever
other
also
part
urgent
call
new
vaccin
challeng
research
capac
academia
privat
manufactur
process
discoveri
part
long
costli
process
initi
test
safeti
efficaci
new
institut
fund
arrang
need
make
new
technolog
genet
vaccin
develop
new
challeng
may
expect
aris
also
need
futur
mauric
hilleman
vaccin
develop
distribut
save
million
live
potenti
save
million
new
vaccin
emerg
public
privat
research
center
pioneer
achiev
next
gener
hilleman
colleagu
scienc
continu
develop
box
global
impact
rubella
vaccin
g
rubella
contagi
gener
mild
viral
infect
occur
often
children
young
adult
g
specif
treatment
rubella
diseas
prevent
vaccin
g
rubella
infect
pregnant
women
may
caus
fetal
death
congenit
defect
known
congenit
rubella
syndrom
cr
g
rubella
pandem
develop
unit
state
babi
born
congenit
rubella
syndrom
g
children
cr
suffer
hear
impair
eyeand
heart
defect
lifelong
disabl
includ
autism
diabet
mellitu
thyroid
disord
new
tool
find
way
produc
vaccin
use
genet
techniqu
ad
key
gene
simpl
microorgan
produc
protect
antibodi
improv
heat
stabil
vaccin
elimin
cumbersom
costli
cold
chain
ie
store
transport
vaccin
within
specifi
temperatur
rang
policymak
public
health
system
continu
improv
vaccin
deliveri
implement
vaccin
program
reduc
morbid
mortal
rate
across
globe
vaccin
among
effici
prevent
measur
avail
clinic
medicin
public
health
howev
gain
success
immun
campaign
roll
back
rate
vaccin
refus
increas
public
support
erod
proand
contraadvocaci
group
public
concern
vaccin
safeti
becom
wildli
exagger
effect
reduc
vaccin
accept
support
medic
practition
media
vital
promot
adopt
accept
newer
vaccin
often
skeptic
public
neither
scienc
applic
advanc
occur
automat
instead
vaccin
discoveri
develop
implement
coverag
requir
skill
dedic
futur
hilleman
welltrain
public
health
workforc
strong
organiz
base
public
health
hilleman
believ
demonstr
academ
industrybas
scientist
could
work
complementari
fashion
support
global
public
health
goal
diseas
control
erad
vaccin
develop
distribut
crucial
role
popul
health
prospect
look
favor
scientif
advanc
lead
new
vaccin
potenti
diseas
control
erad
process
requir
long
expens
period
basic
scienc
research
vaccin
test
proven
effect
safe
implement
immun
program
academicindustri
partnership
govern
support
encourag
improv
effici
vaccin
develop
mani
countri
adopt
new
vaccin
routin
immun
program
proven
slow
cdc
public
framework
prevent
infecti
diseas
emphas
modern
infecti
diseas
surveil
expand
role
public
health
laboratori
diseas
control
prevent
advanc
workforc
develop
train
sustain
strengthen
public
health
practic
commit
leadership
role
nation
govern
diseas
control
depend
monitor
case
report
includ
quantiti
common
factor
time
locat
risk
factor
avail
intervent
appli
control
epidem
endem
diseas
essenti
reach
especi
vulner
group
live
urban
poverti
area
well
remot
villag
particular
risk
factor
diseas
context
vaccin
enorm
social
econom
benefit
well
critic
improv
health
prevent
diseas
avoid
mortal
welltrain
public
workforc
requir
meet
challeng
ultim
ensur
develop
key
prevent
measur
reduceand
case
eradicateinfecti
diseas
requir
public
health
government
leadership
public
health
system
respons
total
popul
health
must
take
lead
financ
organ
monitor
deliv
need
servic
child
vaccin
public
health
wide
suffer
low
prioriti
nation
govern
budget
harmon
immun
polici
public
support
need
resourc
strong
support
nation
govern
polici
fund
key
reduct
incid
preval
control
diseas
amelior
known
well
yettob
discov
vaccin
cdc
consid
vaccin
one
greatest
achiev
biomed
scienc
public
health
cdc
vast
major
vaccin
use
current
develop
th
centuri
basi
loui
pasteur
work
anthrax
rabi
th
centuri
vaccin
develop
mauric
hilleman
academ
industri
colleagu
merck
colleg
physician
philadelphia
hilleman
undoubtedli
lead
vaccinologist
th
centuri
perhap
time
award
nation
medal
scienc
highest
scientif
honor
unit
state
although
receiv
mani
profession
honor
never
achiev
popular
recognit
fame
pioneer
vaccin
develop
implement
develop
leader
poliomyel
vaccin
jona
salk
albert
sabin
hilleman
award
albert
sabin
gold
medal
award
dr
anthoni
fauci
director
us
nation
institut
allergi
infecti
diseas
us
nation
institut
health
call
hilleman
one
true
giant
scienc
medicin
public
health
centuri
hilleman
die
truli
magnific
scientif
career
year
dr
paul
offit
chief
infecti
diseas
children
hospit
philadelphia
told
bmj
commit
make
someth
use
convert
clinic
use
mauric
geniu
develop
vaccin
reliabl
reproduc
charg
pharmaceut
facet
research
marketplac
bmj
obituari
hilleman
state
almost
hilleman
career
pharmaceut
industri
develop
cooper
academ
scientist
vaccin
brought
scienc
direct
benefit
mankind
save
million
death
especi
children
dr
faucci
state
mauric
perhap
singl
influenti
public
health
figur
twentieth
centuri
one
consid
million
live
save
countless
peopl
spare
suffer
work
cours
career
mauric
colleagu
develop
forti
vaccin
fourteen
vaccin
current
recommend
unit
state
mauric
develop
eight
although
larg
unknown
among
gener
public
even
among
public
health
practition
teacher
mauric
hilleman
outstand
scientist
field
vaccinolog
th
centuri
brought
dynam
creativ
develop
vaccin
save
countless
live
bring
mean
hope
erad
import
diseas
measl
congenit
rubella
syndrom
hepat
b
introduc
new
approach
vaccinolog
other
follow
path
use
help
controlor
eliminateimport
diseas
other
futur
may
face
human
hope
new
hilleman
emerg
advanc
scienc
genet
vaccinolog
face
exist
new
challeng
scienc
popul
health
progress
vaccinolog
applic
reli
fund
priorit
monitor
surveil
routin
immun
program
outbreak
control
cornerston
public
health
goal
diseas
control
erad
public
health
must
improv
leadership
respons
realiz
import
role
reach
atrisk
vulner
segment
popul
outli
rural
area
urban
dweller
lowincom
countri
halt
resurg
achiev
erad
still
signific
diseas
includ
measl
rubella
target
vaccineprevent
diseas
come
year
public
health
increas
advocaci
effort
health
promot
extend
vaccin
develop
assur
public
support
measl
control
erad
well
vaccineprevent
diseas
resourc
scienc
advanc
servic
deliveri
equal
import
must
accept
government
respons
lmic
well
highincom
countri
train
public
health
commun
health
worker
vital
meet
old
new
vaccin
challeng
prematur
death
diseas
disabl
age
popul
sever
climat
social
inequ
challeng
govern
academ
research
center
vaccin
manufactur
public
health
author
requir
welldesign
plan
respond
pandem
ill
especi
recogn
global
import
urgenc
need
quicker
develop
distribut
influenza
vaccin
well
newli
emerg
infecti
diseas
ebola
zika
among
other
